MENINGOCOCCAL MENINGITIS

More documents

Recommendations

Info

Vaccines A, C, W135 or Y vaccines available close contacts who received chemoprophylaxis should be offered vaccination early as possible up to 4 weeks after the onset Mencavax AC (bivalent) Mencevax ACWY (quadrivalent quadrivalent) )
Dissemination of information Household contacts Group settings eg nurseries, schools Response team: Public health physician Environmental health inspector School health and safety officer School/group management
Page 1 and 2: MENINGOCOCCAL MENINGITIS Dr. Charma
Page 3 and 4: Types of Meningitis
Page 5 and 6: Meningococcal Disease Severe bacte
Page 7 and 8: Aetiological agent The causative a
Page 9 and 10: Neisseria meningitidis 3 serogroups
Page 11 and 12: Nasopharyngeal carriage Neisseria
Page 13 and 14: Incubation period and Infectivity
Page 15 and 16: Signs and Symptoms Meningococcal Me
Page 17 and 18: Petechial rash
Page 19 and 20: Necrotic rash
Page 21 and 22: Petechial rash
Page 23 and 24: Other signs and symptoms Acute fev
Page 25 and 26: “Meningitis Meningitis belt” be
Page 27 and 28: Meningococcal disease Statuatory n
Page 29 and 30: Collect Information Record basic in
Page 31 and 32: Case ascertainment EU Case Definit
Page 33 and 34: Case classification Probable case:
Page 35 and 36: Family Slide
Page 37 and 38: Prophylactic treatment Risk assess
Page 39 and 40: Prophylaxis NOT indicated Staff an
Page 41: Chemoprophylaxis : CIPROFLOXACIN 5
Page 45 and 46: Managing clusters Assess the infor
Page 47 and 48: Control Strategy Communicable dise
Page 49 and 50: Case fatality rate Proportion of c
Page 51 and 52: AGE SPECIFIC INCIDENCE RATES Incide
Page 53: Thank you charmaine.gauci@gov.mt

MENINGOCOCCAL MENINGITIS

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?